Skip to content
DataLookout
Menu

Sanofi clinical trial pipeline

Get alerts when Sanofi's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20

What changed in the last 30 days

48 trials changed in the last 30 days: 2 stopped, 10 with notable changes, 36 with minor changes only.

  1. Minor: Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) Trial completed Provention Bio, a Sanofi CompanyNot specified NCT04598893
  2. Minor: DUPILAB · Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab Primary and study completion pushed from May 10, 2028 to Jul 5, 2028 SanofiNot specified NCT06169527
  3. Minor: COLOR UC · Brivekimig · Ulcerative Colitis Trial sites reduced: 69 → 61 locations SanofiPhase 2 NCT06975722
  4. Notable: Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Phase changed: Phase 2 → Phase 1/2 SanofiPhase 1/2 NCT07756957
  5. Minor: VITALIZE · Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial sites expanded: 133 → 138 locations SanofiPhase 3 NCT06290141
  6. Minor: PERSEPHONE · Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Trial sites expanded: 314 → 322 locations SanofiPhase 3 NCT07190209
  7. Minor: COLOSSUS · Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD) Trial sites expanded: 8 → 16 locations SanofiPhase 3 NCT07793409
  8. Minor: Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry Trial sites expanded: 318 → 324 locations Genzyme, a Sanofi CompanyNot specified NCT00358943
  9. Minor: Fabry Disease Registry & Pregnancy Sub-registry Trial sites expanded: 284 → 289 locations Genzyme, a Sanofi CompanyNot specified NCT00196742
  10. Notable: Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older Recruitment opened SanofiPhase 3 NCT07890454
  11. Minor: Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age Enrollment closed, study ongoing SanofiPhase 1 NCT07516418
  12. Minor: Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD) Trial completed SanofiNot specified NCT04848779
  13. Minor: SAR444336 · Microscopic Colitis in Clinical Remission Enrollment closed, study ongoing SanofiPhase 2 NCT07156175
  14. Minor: Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 Enrollment closed, study ongoing SanofiPhase 4 NCT07861542
  15. Minor: Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease · IVS4 Mutation in Taiwan Trial completed SanofiNot specified NCT06052800
  16. Minor: LUNA 4 · Oral Rilzabrutinib · Immune Thrombocytopenia (ITP) Who Failed First-line Treatment Trial sites expanded: 36 → 54 locations SanofiPhase 3 NCT07007962
  17. Minor: RESULT · Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease Trial sites expanded: 79 → 82 locations SanofiPhase 2 NCT06500702
  18. Minor: Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants Primary and study completion pushed from Sep 28, 2026 to Jan 26, 2027 SanofiPhase 1 NCT07726914
  19. Minor: Rilzabrutinib for the Adult · Chronic ITP Who Have Completed Phase 3 Study in Japan Final enrollment: 3 participants (planned 4) SanofiPhase 3 NCT07216079
  20. Minor: Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) Start date pushed from Oct 30, 2026 to Nov 20, 2026 SanofiPhase 4 NCT07135973
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-18 NCT07944885 First-in-human Study of SAR448632 in Healthy Adult Participants Phase 1 Not Yet Recruiting
2026-11-17 NCT07941622 Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B… Phase 3 Not Yet Recruiting
2026-11-12 NCT07930624 A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants… Phase 3 Not Yet Recruiting
2026-11-10 NCT07927140 The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2… Phase 3 Not Yet Recruiting
2026-11-06 NCT07923305 Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults… Phase 2/3 Not Yet Recruiting
2026-11-06 NCT07923383 An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected… Phase 1 Not Yet Recruiting
2026-11-05 NCT07919899 Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and… Phase 3 Not Yet Recruiting
2026-10-30 NCT07906132 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and… Completed
2026-10-29 NCT07905508 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and… Completed
2026-10-29 NCT07905534 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and… Active, Not Recruiting

Active trials by phase

Phase 1
13
Phase 1/2
15
Phase 2
37
Phase 2/3
3
Phase 3
56
Phase 4
13
Not charted: 42 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 21

Get alerts when Sanofi's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free